of Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • June 22nd, 2010 • Peregrine Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Colorado
Contract Type FiledJune 22nd, 2010 Company Industry JurisdictionPeregrine Pharmaceuticals, Inc. a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with McNicoll, Lewis & Vlak LLC, a Delaware limited liability company (“MLV”), as follows: